Insulet — Aug 5, 2026 release

Omnipod revenue of $544.1 million, increased 20.1% ▪ International Omnipod revenue of $251.8 million, increased 35.5%, or 32.9% in constant currency ◦ Drug Delivery revenue of $5.8 million • Operating income of $129.7 million, or 16.2% of revenue, down 250 basis points over prior year • Adjusted operating income 1 of $154.5 million, or 19.3% of revenue, up over 140 basis points compared to prior year • Net income of $95.0 million, or $1.37 per diluted share, compared to $22.5 million, or $0.32 per diluted share, in the prior year • Adjusted net income 1 of $115.0 million, or $1.66 per diluted share, increased 37.4% and 41.5%, respectively, compared to $83.7 million, or $1.17 per diluted share, in the prior year Recent Strategic Highlights: • Launched Omnipod 5 and Omnipod Discover TM in Spain, expanding access to tubeless diabetes technology. Spain is the 26 th country where Insulet sells Omnipod, and the 20 th country where Omnipod 5 is available, further accelerating Insulet’s mission to transform the lives of people with diabetes around the world • Expanded the Omnipod 5 ecosystem through the launch of next-generation algorithm designed to improve time in range and increase time spent in Automated Mode, while broadening sensor choice through expanded compatibility with Abbott’s FreeStyle Libre 3 Plus • Presented data at the American Diabetes Association 2026 Scientific Sessions reinforcing the strength of its innovation pipeline and next-generation automated insulin delivery technologies ◦ STRIVE results supporting